|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,268.10 INR | +0.86% |
|
-0.19% | +7.39% |
| 06-05 | Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments | MT |
| 06-04 | Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 2,468.53 | +8.84% | 38 | ||||||
| 1,215.1 | +7.4% | 29 | ||||||
| 252.87 | +8.63% | 23 | ||||||
| 253.55 | +11.58% | 29 | ||||||
| 360.76 | +10.29% | 17 | ||||||
| 129.74 | +7.41% | 27 | ||||||
| 221.42 | +19.45% | 21 | ||||||
| 155.2 | +4.53% | 21 | ||||||
| 311.78 | +9.84% | 23 | ||||||
| 352.23 | +0.76% | 30 | ||||||
| 157.83 | +22.2% | 29 | ||||||
| 29.19 | +12.09% | 27 | ||||||
| 63.08 | +10.14% | 25 | ||||||
| 548.69 | +22.8% | 29 | ||||||
| 97.1 | +24.56% | 23 | ||||||
| 20.83 | +7.47% | 20 | ||||||
| 9,973.33 | +32.03% | 15 | ||||||
| 6,136.87 | +24.58% | 15 | ||||||
| 81.26 | +72.61% | 16 | ||||||
| Average | 1,201.55 | +16.70% | 24 | ||||||
| Weighted average by Cap. | 687.1 | +11.42% | 25 |
- Stock Market
- Equities
- 500257 Stock
- Sector Lupin Limited
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition